Aug 1 (Reuters) - Medical equipment maker ResMed ( RMD )

reported fourth-quarter revenue in line with estimates on

Thursday, on steady demand for its sleep apnea treatment

devices.

The company's quarterly revenue rose 9% to $1.22 billion, in

line with estimates of $1.22 billion.

ResMed ( RMD ) makes ventilators and machines that provide

continuous and bilateral positive airway pressure, known as CPAP

and BIPAP, which are used for non-invasive treatment of sleep

apnea.

Sleep apnea is a condition where the airway gets blocked

multiple times while sleeping.

The California-based company reported adjusted profit of

$2.08 per share for the quarter ended June 30, narrowly beating

estimates of $2.07 per share, according to LSEG data.

Separately, Eli Lilly ( LLY ) said in June that its popular

weight-loss drug Zepbound helped resolve moderate to severe

obstructive sleep apnea in up to 52% of patients in two

late-stage trials.

ResMed ( RMD ) has previously shrugged off concerns over weight-loss

drugs such as Novo Nordisk's Wegovy and Eli Lilly's ( LLY )

Zepbound being tested to treat sleep apnea.

Shares of the company were down 4.7% at $204.51 after the

bell.